conomic value of medicines, medical devices and other technologies is an increasingly important consideration in healthcare management. Conducting high quality economic analyses alongside randomised controlled clinical trials (RCTs) is desirable since these offer timely information with high internal validity. The recent publication of the landmark PROactive study provides a relevant platform upon which to base a detailed economic evaluation of the possible additional benefit of pioglitazone over and above current best treatment in patients with type 2 diabetes with severe cardiovascular (CV) disease. Pioglitazone improved CV outcome and reduced the need to add insulin to existing therapy in individuals at high risk of further macrovascular events. The predefined economic analysis of this study using well-accepted methods will inform the cost effectiveness (CE) of pioglitazone confirming (or not) its value in the management of patients with type 2 diabetes with severe CV disease.
Fisher M., Shaw K.Diabetes: a state of premature cardiovascular death. Pract Diab Int2001;18:183-4.
2.
Wild S., Roglic G., Green A., Sicree R., King H.Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care2004;24:1047-53.
3.
Roper NA, Bilous RW, Kelly WF, Unwin NC, Connolly VMExcess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. BMJ2001;322:1389-93.
4.
Almdal T., Scharling H., Jensen JS, Vestergaard H.The independent effect of type 2 diabetes mellitus on ischaemic heart disease, stroke and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med2004;164:1422-6.
5.
Scandinavian Simvastatin SurvivalStudy Group.Randomised trial of cholesterol lowering in 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet1994 ;344:1383-9.
6.
Rubins HB, Robins SJ, Collins D. et al. for the Veterans Affairs High Density Lipoprotein Cholesterol Intervention Trial Study Group.Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med1999;341:410-18.
7.
UK Prospective Diabetes Study (UKPDS) Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes. UKPDS 33. Lancet1998 ;352:837-53.
8.
Bottomley JMManaging care of type 2 diabetes. Learnings from T2ARDIS. Br J Diabetes Vasc Dis2001 ;1:68-72.
9.
Williams R., Baxter H., Bottomley J. et al. CODE-2*UK: Our contribution to a European Study of the costs of Type 2 diabetes. Practical Diabetes International2001;18:235-8.
10.
Currie C., Morgan CL, Peters JRPatterns and costs of hospital care for coronary heart disease related and not related to diabetes. Heart1997;78:544-54.
11.
Baghurst A. , Hopkinson PK, Maier W., Currie CJAn economic model of the long-term health care burden of Type II diabetes. Diabetologia2001;44:2140-55.
12.
Baghurst A. , Hopkinson PK, Maslove L., Currie CJThe projected health care burden of Type 2 diabetes in the UK from 2000 to 2060. Diabetic Medicine2002;19(suppl 4):1-5.
13.
Caro JJ, Ward AJ, O'Brien JALifetime costs of complications resulting from type 2 diabetes in the US. Diabetes Care2002;25:476-81.
14.
National Diabetes Data Group.Diabetes in America. 2nd ed. 1995 . National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases. NIH Publication No. 95-1468.
15.
Improving Diabetes Services - The NSF Two Years on, Department of Health Diabetes Team, 23 March 2005. Accessed on www.dh.gov.uk/PolicyAndGuidance/HealthAndSocialcareTopics/Diabetes
16.
Haffner SM, D'Agostino R. Jr, Mykkanen L. et al. Insulin sensitivity in subjects with type 2 diabetes: relationship to cardiovascular risk factors: The Insulin Resistance Atherosclerosis Study . Diabetes Care1999;22:562-8.
UK Prospective Diabetes Study (UKPDS) Group.Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes. UKPDS 40. BMJ1998;317:720-6.
19.
Gray A., Raikou M., McGuire A.Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial. UKPDS Group 41. BMJ2000; 320:1373-8.
20.
White JREconomic considerations in treating patients with type 2 diabetes mellitus . Am J Health System Pharm2002;59(suppl 9):S14-S17.
21.
Wagner EH, Sandhu N., Newton KM, McCullough DK, Ramsey SD, Grohaus LCEffects of improved glycemic control on health care costs and utilization . JAMA2000;285:182-9.
22.
Testa MA, Simonson DCHealth economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes: a randomised, controlled clinical trial . JAMA1998;280:1490-6.
23.
Meier JL, Swislocki AL, Lopez JR, Noth RH, Bartlebaugh P., Siegel D.Reduction in self-monitoring of blood glucose in persons with type 2 diabetes results in cost savings and no change in glycemic control. Am J Manag Care2002;8:557-65.
24.
UK Prospective Diabetes Study (UKPDS) Group.Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UKPDS Group. Lancet1998;352:854-65.
25.
Clarke PM, Gray AM, Briggs A., Stevens RJ, Matthews DR, Holman R.Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes. UKPDS 72. Diabetologia2005;48:868-77.
26.
Gaede P., Vedel P., Larsen N., Jensen GV, Parving HH, Pedersen O.l. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med2003;348:383-93.
27.
Ukpds 37.Quality of life in Type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control. UKPDS Study Group . Diabetes Care1999;22:1125-36.
28.
Ukpds 62.Clarke P., Gray A., Holman R.Estimating utility values for health states of type 2 diabetic patients using the EQ-5D. Medical Decision Making2002;22:340-9.
29.
Baghurst A. , Beale S.Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Economics2005; 14:217-30.
30.
Coffey JT, Brandle M., Zhou H. et al. Valuing health-related quality of life in diabetes. Diabetes Care2002;25:2238-43.
31.
The FIELD study investigators.Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet2005;366:1849-61.
32.
Goldberg RB , Kendall DM, Deeg MA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care2005;28:1547-54.
33.
Derosa G., Cicero AF, Gaddi A. et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther2004;26:744-54.
34.
Chiquette E. , Ramirez G., Defronzo R.A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med2004;164:2097-104.
35.
Tilden DP, Mariz S., O'Bryan-Tear G., Diamantopoulos A.A lifetime economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. Poster presentation ISPOR 2005, Florence, November 2005.
36.
Pyorala K., Pedersen TR, Kjekshus J., Faergeman O., Olsson AG, Thorgeirsson G.Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care1997;20:614-20.
37.
UK Prospective Diabetes Study (UKPDS) Group.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. (UKPDS 38). BMJ1998;317:703-13.
38.
Kannel WB, Neaton JD, Wentworth D. et al. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT Multiple Risk factor Intervention Trial. Am Heart J1986 ;112:825-36.
39.
Hansson L., Zanchetti A., Carruters SG et al. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principle results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet1998;351:1755-62.
40.
Feinglos MN , Bethal MATherapy of type 2 diabetes, cardiovascular death and the UGDP. Am Heart J1999;138:S346-52.
41.
Clarke P., Gray A., Adler A. et al. Cost effectiveness analysis of intensive blood glucose control with metformin in overweight patients with Type II diabetes (UKPDS 51). Diabetologia2001;44:298-304.
42.
Clarke P., Gray A., Legood R., Briggs A., Holman R.The impact of diabetes-related complications on healthcare costs (UKPDS Study 65). Diabetic Medicine2003;20:442-50.
43.
Nyman JA, Martinson MS, Nelson D. et al. Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol. Arch Intern Med2002;162:177-82.
44.
Schädlich PK , Brecht JG, Rangoonwala B., Huppertz E.Cost effectiveness of Ramipril in patients at high risk for cardiovascular events. Economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) Study for Germany from the Statutory Health Insurance Perspective. Pharmacoeconomics2004 ;22:955-73.
45.
Grover SA, Alexander CM, Coupla L., Weiss TW, Zowall H., Gomes DRJ.How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease?Diabetes Care2001;24:45-50.
46.
Jönsson B., Cook JR, Pedersen TRThe cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia1999 ;42:1293-301.
47.
Brandle M., Davidson MB, Scriger DL, Lorber B., Herman WHCost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes. Diabetes Care2003;26:1796-801.
48.
Jönsson B., Hansson L., Stålhammer N.-O.Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. J Int Med2003 ;253:472-80.
49.
Continued on page 70 Continued from page 68
50.
Rippin JD, Barnett AH, Bain SCCost-effective strategies in the prevention of diabetic nephropathy. Pharmacoeconomics2004;22:9-28.
51.
Palmer AJTucker DMValentine WJRoze S.Gabriel S.Cordonnier DJCost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studiesNephrology Dialysis Transplantation2005; 20:1103-09.
52.
Burgess ED, Carides GW, Girth WC, Marentette MA, Chabot I.Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective. Can J Cardiol2004 ;20:613-18.
53.
Charbonnel B., Dormandy J., Erdmann E., Massi-Benedetti M., Skene A.: The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive) . Diabetes Care2004;27:1647-53.
54.
see www.proactive-results.com
55.
Dormandy JA , Charbonnel B., Eckland DJA et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet2005;366:1279-89.
56.
A desktop guide to type 2 diabetes mellitus: European Diabetes Policy Group1999. Diabet Med1999;16:716-30.
57.
Yki-Järvinen H.The PROactive study: some answers, many questions . Lancet2005;366:1241-2.
58.
Palmer AJ, Roze S., Valentine WJ et al. The CORE Diabetes Model: Projecting Long-term outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (Types 1 and 2) to support clinical and reimbursement decision-making. Current Medical Research and Opinions2004;20:S5-S26.
59.
Palmer AJ, Roze S., Valentine W. et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin2004 ;20:S27-S40.
60.
Saydah SH, Fradkin J., Cowie CCPoor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA2004;291:335-42.
61.
National Diabetes Audit.Key findings about the quality of care for people with diabetes in England. National Clinical Audit Support Programme. September 2005. Document Reference: 2005-IC-0025. Report available at www.icservices.nhs.uk/ncasp/pages/audit_topics/diabetes
62.
Improving Diabetes Services - The NSF Two Years on, Department of Health Diabetes Team, 23 March 2005. Accessed on www.dh.gov.uk/PolicyAndGuidance/HealthAndSocialcareTopics/Diabetes
63.
Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet2004;364:685-96.
64.
Heart Outcomes Prevention Evaluation (HOPE) Study Investigators.Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE and MICRO-HOPE sub-study. Lancet2000 ;355:253-9.
65.
Heart Protection StudyCollaborative Group.MRC/BHF Heart protection Study of cholesterol-lowering with simvastatin in 5953 people with diabetes: a randomised placebo-controlled trial. Lancet2003;361:2005-16.
